Abstract
Disposition of [ 14C] bumetanide administered intravenously to four healthy volunteers could be described by a triexponential equation. The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively. The largest fraction of dose was eliminated during the second phase; only 17% was eliminated during the last phase. The total plasma clearance averaged 228 ml/min, with renal clearance about one-half of this value. The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose. In plasma 93% of bumetanide was bound to proteins. Thus bumetanide is rapidly eliminated by both renal and nonrenal mechanisms. The elimination kinetics resembled those described for furosemide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. J. Asbury, P. B. B. Gatenby, S. O'Sullivan, and E. Bourke. Bumetanide: Potent new “loop” diuretic.Br. Med. J. 1:211–213 (1972).
D. L. Davies, A. F. Lant, N. R. Millard, A. J. Smith, J. W. Ward and G. M. Wilson. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.Clin. Pharmacol. Ther. 15:141–155 (1974).
K. H. Olesen, B. Sigurd, E. Steiness, and A. Leth. Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.Acta Med. Scand. 193:119–131 (1973).
W. R. Murdoch, and W. H. R. Auld. Bumetanide—acute and long term studies of a new high potency diuretic.Postgrad. Med. J. 51:10–14 (1975).
L. E. Ramsay, G. T. McInnes, J. Hettiarachchi, J. Shelton, and P. Scott: Bumetanide and frusemide: A comparison of dose-response curves in healthy men.Br. J. Clin. Pharmacol. 5:243–247 (1978).
P. J. Pentikäinen, A. Penttilä, P. J. Neuvonen, and G. Gothoni. Fate of [14C]bumetanide in man.Br. J. Clin. Pharmacol. 4:39–44 (1977).
S. C. Halladay, I. G. Sipes, and D. E. Carter. Diuretic effect and metabolism of bumetanide in man.Clin. Pharmacol. Ther. 22:179–187 (1977).
P. W. Feit, K. Roholt, and H. Sorenson. GLC determination and urinary recovery of bumetanide in healthy volunteers.J. Pharm. Sci. 62:375–379 (1973).
S. C. Halladay, D. E. Carter, I. G. Sipes, B. B. Brodie, and R. Bressler. Evidence for the metabolism of bumetanide in man.Life Sci. 17:1003–1010 (1975).
C. M. Metzler, G. L. Elfring, and A. J. McEven. A package of computer programs for pharmacokinetic modelling.Biometrics 30:562 (1974).
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
N.-E. Saris. Differentiation of free and protein bound sulfonamide with the aid of Sephadex G-25.Acta Chem. Scand. 17:872 (1963).
L. Z. Benet. Pharmacokinetics/pharmacodynamics of furosemide in man: A review.J. Pharmacokin. Biopharm. 7:1–27 (1979).
W. Rupp and P. Hajdú. Pharmacokinetics and pharmacodynamics of a diuretic agent. In H. J. Dengler (ed.),Symposium on Pharmacological and Clinical Significance of Pharmacokinetics F. K. Schattauer Verlag, Stuttgart, 1970, pp. 105–111.
C. M. Huang, A. J. Atkinson, Jr., M. Levin, N. W. Levin, and A. Quintanilla. Pharmacokinetics of furosemide in advanced renal failure.Clin. Pharmacol. Ther. 16:659–666 (1974).
B. Calesnick, L. J. Christensen, and N. Richter. Absorption and excretion of furosemide S35 in human subjects.Proc. Soc. Exp. Biol. Med. 123:17–22 (1966).
F. Andreasen and P. Jakobsen. Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.Acta Pharmacol. Toxicol. 35:49–57(1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pentikäinen, P.J., Neuvonen, P.J., Kekki, M. et al. Pharmacokinetics of intravenously administered bumetanide in man. Journal of Pharmacokinetics and Biopharmaceutics 8, 219–228 (1980). https://doi.org/10.1007/BF01059643
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059643